Ultromics granted FDA Breakthrough Device Status
Ultromics has gained FDA Breakthrough Device Designation for its AI-powered EchoGo Amyloidosis platform, which is speeding up diagnosis.
AI and Analytics
Ultromics AI platform to expand trials to 20 NHS hospitals
A British AI platform for assisting with the diagnosis of heart disease will enter trials with 20 NHS hospitals before the end of 2018, after securing £10 million in first-round funding.
AI and Analytics